Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
C4 Therapeutics (Nasdaq: CCCC) reported second quarter 2026 revenue of $6.6 million versus $6.5 million a year earlier, with a net loss of $23.6 million ($0.18 per share) compared to $26.0 million ($0.37 per share) in 2025. R&D and G&A expenses declined slightly year over year.
Cash, cash equivalents and marketable securities totaled $300.4 million at June 30, 2026, supported by $33.5 million raised via an at-the-market program and a $20 million upfront payment from a new degrader‑antibody conjugate collaboration with Roche. According to C4 Therapeutics, this cash runway is expected to fund operations into the end of 2028.
Clinically, updated Phase 1 data for cemsidomide in multiple myeloma showed overall response rates of 40% and 53% at the two highest doses with no cemsidomide‑related discontinuations, which the company says support a differentiated profile. Multiple ongoing and planned cemsidomide trials remain on track, with key data readouts expected in 2027.
C4 Therapeutics (Nasdaq: CCCC) reported that the independent directors on its Organization, Leadership and Compensation Committee approved an inducement grant of non-qualified stock options to purchase 162,880 shares of common stock for one new employee, effective August 10, 2026.
According to C4 Therapeutics, the grant was made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing price of C4T’s common stock on the grant date. The options vest over four years: 25% after one year, then the remainder in 36 equal monthly installments, contingent on continued employment.
C4 Therapeutics (Nasdaq: CCCC) reported updated Phase 1 data for cemsidomide, an oral IKZF1/3 degrader, in relapsed/refractory multiple myeloma at the EHA 2026 Congress.
At the 100 µg RP2D, overall response rate was 53%, with MRD-negative complete responses, a 7.9‑month median response duration and a generally manageable safety profile in heavily pretreated patients.
C4 Therapeutics (Nasdaq: CCCC) announced management participation in several upcoming healthcare and oncology conferences. Events include TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026, the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.
Fireside chats and 1x1 meetings will be held virtually and in person, with live webcasts and 90‑day archived replays accessible via the company’s investor relations website.
C4 Therapeutics (Nasdaq: CCCC) approved an inducement grant of non-qualified stock options to purchase 85,480 shares of common stock for one new employee, effective May 18, 2026.
The options’ exercise price equals the closing stock price on the grant date and vest over four years, subject to continued employment.
C4 Therapeutics (Nasdaq: CCCC) reported first quarter 2026 revenue of $6.2 million, down from $7.2 million a year earlier, and a net loss of $25.1 million or $0.20 per share.
The company advanced multiple myeloma degrader cemsidomide with ongoing Phase 2 MOMENTUM and Phase 1b elranatamab combination trials and plans another Phase 1b combo study in 1H 2027. A new Roche collaboration on degrader-antibody conjugates brought a $20 million upfront payment. Cash, cash equivalents and marketable securities were $268.3 million on March 31, 2026, with funding expected to last through year-end 2028. C4 Therapeutics decided not to advance CFT8919 for EGFR-mutated NSCLC outside Greater China.
C4 Therapeutics (Nasdaq: CCCC) expanded its long-term partnership with Roche on April 9, 2026 to discover and develop degrader-antibody conjugates (DACs) for oncology. The agreement covers two collaboration-exclusive programs, an option for a third target, and combines C4T's TORPEDO platform with Roche's ADC expertise.
Financial terms include a $20 million upfront payment, additional payment if Roche exercises a third-target option, near-term discovery milestones, eligibility for over $1 billion in discovery, regulatory and commercial milestones, and tiered royalties on future sales.
C4 Therapeutics (Nasdaq: CCCC) announced the first patient has been dosed in a Phase 1b trial of oral cemsidomide plus dexamethasone with FDA-approved elranatamab (ELREXFIO) for relapsed/refractory multiple myeloma.
The open-label, multicenter study will enroll up to 54 patients, test 50/75/100 µg cemsidomide doses, assess safety/tolerability as the primary endpoint, and aims to report Phase 1b data in mid-2027. Pfizer supplies elranatamab at no cost per the collaboration.
C4 Therapeutics (Nasdaq: CCCC) announced an inducement non-qualified stock option grant of 85,480 shares to one new employee, approved March 9, 2026. The exercise price equals the closing market price on the grant date. Vesting: four years with 25% after year one, then 36 monthly installments.
The grant was made as a material inducement under Nasdaq Listing Rule 5635(c)(4) and is subject to continued employment through each vesting date.
C4 Therapeutics (Nasdaq: CCCC) reported 2025 results and program progress on Feb 26, 2026. Key items: cemsidomide moved into a Phase 2 MOMENTUM trial with first patient dosed and a recommended Phase 2 dose of 100 µg. Cash, cash equivalents and marketable securities were $297.1M at Dec 31, 2025, providing runway to the end of 2028. Company raised $125M in October 2025 and earned a $2M Biogen milestone; Phase 1b combo trial with elranatamab is on track for Q2 2026.